5 Analysts Have This to Say About Catalyst Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have given their opinion on Catalyst Pharmaceuticals (NASDAQ:CPRX) stock. The average price target is $24.2, implying an upside from the current price of $15.02. The majority of the ratings are bullish, with 4 out of 5 analysts giving a positive outlook.
August 11, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a bullish outlook on Catalyst Pharmaceuticals (NASDAQ:CPRX) with an average price target of $24.2, indicating potential growth from the current price.
The bullish outlook from the majority of analysts indicates a positive sentiment towards the stock. The average price target of $24.2 is significantly higher than the current price, suggesting potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100